BioCryst Pharmaceuticals reports strong financial results for 2024, expects positive growth in 2025.
From GlobeNewswire: 2025-02-24 07:00:00 BioCryst Pharmaceuticals reported strong financial results for Q4 2024, with ORLADEYO net revenue up 36.6% y-o-y